EMA/105425/2024

European Medicines Agency decision

P/0109/2024

of 12 April 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for belimumab (Benlysta), (EMEA-000520-PIP03-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0109/2024

of 12 April 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for belimumab (Benlysta), (EMEA-000520-PIP03-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by GlaxoSmithKline (Ireland) Limited on 7 February 2023 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 February 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for belimumab (Benlysta), powder for concentrate for solution for infusion, solution for injection, intravenous use, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for belimumab (Benlysta), powder for concentrate for solution for infusion, solution for injection, intravenous use, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for belimumab (Benlysta), powder for concentrate for solution for infusion, solution for injection, intravenous use, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/254/2009 issued on 22/12/2009 and in decision P/0276/2014 issued on 28/10/2014, including subsequent modifications thereof.

Article 5

This decision is addressed to GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, 24 – Dublin, Ireland.

EMA/PDCO/537772/2023
Amsterdam, 23 February 2024

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-000520-PIP03-23

Scope of the application

Active substance(s):

Belimumab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of systemic sclerosis

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Solution for injection

Route(s) of administration:

Intravenous use

Subcutaneous use

Name/corporate name of the PIP applicant:

GlaxoSmithKline (Ireland) Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, GlaxoSmithKline (Ireland) Limited submitted for agreement to the European Medicines Agency on 17 February 2023 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 27 March 2023.

Supplementary information was provided by the applicant on 10 November 2023. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of systemic sclerosis

The waiver applies to:

- the paediatric population from birth to less than 8 years of age;
- powder for concentrate for solution for infusion, solution for injection, intravenous use, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of systemic sclerosis

2.1.1. Indication(s) targeted by the PIP

Treatment of systemic sclerosis

Treatment of interstitial lung disease associated with systemic sclerosis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 8 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1: Single arm, open-label study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of belimumab solution for injection, subcutaneous use, in children from 8 years to less than 18 years of age with juvenile onset systemic sclerosis and to provide PK/PD data

	to support the extrapolation of efficacy from the adult population.
Modelling and simulation analyses	Study 2: Modelling and simulation analyses to predict initial paediatric doses to be used in the paediatric clinical study (PIP Study 1).
Other studies	Not applicable
Extrapolation plan	Studies 1 and 2 are part of an extrapolation plan covering the paediatric population from 8 years to less than 18 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2031
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of systemic sclerosis

Belimumab is not yet authorised in the treatment of systemic sclerosis, below are the authorised indications for Belimumab.

2. Treatment of systemic lupus erythematosus

Authorised indication(s):

- Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy
  - Invented name(s): Benlysta
  - Authorised pharmaceutical form(s): Powder for concentrate for solution for infusion
  - Authorised route(s) of administration: Intravenous use
  - Authorised via centralised procedure
- Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy
  - Invented name(s): Benlysta
  - Authorised pharmaceutical form(s): Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe
  - Authorised route(s) of administration: Subcutaneous use
  - Authorised via centralised procedure
- Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis
  - Invented name(s): Benlysta
  - Authorised pharmaceutical form(s): Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe
  - Authorised route(s) of administration: Intravenous use, Subcutaneous use
  - Authorised via centralised procedure